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Introduction
Superior Vena Cava (SVC) syndrome is often associated with a malignancy that causes obstruction of the SVC resulting in
decreased venous drainage from the head and neck. It most commonly presents with neck, facial, and upper extremity
swelling, dyspnea or cough. The clinical effects of SVC syndrome range from mild aesthetic disturbances to life-threatening
situations and hemodynamic instability. Increased venous pressure and edema may compromise the larynx and pharynx,
leading to symptoms of stridor and dysphagia. Furthermore, confusion and coma may result from increased cerebral edema.
Therefore prompt recognition and treatment is necessary.

Case Report
A 34-year-old Caucasian female presented with dyspnea and a two-month history of facial swelling and discoloration,
exacerbated when bending over. Past medical history was significant for methylenetetrahydrofolate reductase deficiency, history
of provoked pulmonary embolism, and T2N0 left breast infiltrating ductal carcinoma. The patient was receiving chemotherapy
through a right jugular venous catheter, inserted 4 months ago. On physical exam, the patient had facial cyanosis and edema
extending to the anterior chest, tachycardia and decreased breath sounds. A chest wall medi-port was in place, terminating
in the SVC. The remainder of her exam was within normal limits. A CT scan of the neck, chest abdomen and pelvis revealed
acute thrombosis within the SVC and extensive collaterals throughout the pericardium, esophagus, and back musculature.
Subsegmental bilateral pulmonary emboli were noted within the lower lobes. A superior venocavogram revealed totally occlusive
thrombus in the mid to lower portion of the SVC and a small non-occlusive thrombus in the upper portion of the SVC. The right
jugular venous port was present with the tip in the midportion of the SVC with the SVC occluded below the level of the catheter
tip. The patient was subsequently started on a heparin drip and underwent catheter directed tPA. After 16.5 hours of tPA repeat
superior venacavogram showed that the previous
thrombus in SVC had only a small decrease in size with
the development of several tiny channels of flow around
the thrombus to the right atrium. The residual thrombus
was macerated first with a 4 mm diameter angioplasty
balloon followed by a 6 mm diameter angioplasty balloon
to create multiple small flow channels. tPA thrombolysis
was continued for an additional 45.5 hours for a total
of 62 hours. Repeat superior venacavogram showed
excellent flow in the SVC with minimal fibrin sheath
arising from the catheter tip. The patient had no bleeding
complications from tPA therapy and the patient’s facial
cyanosis and edema significantly improved. The venous
catheter was removed 3 days later and patient was
Image 1. Ct scan showing occluded SVC with collateral
Image 2. Venogram showing occlusion of
vessels.
SVC below level of catheter tip.
discharged home on enoxaparin.

Discussion
•	SVC syndrome is most commonly caused by obstruction of the SVC by invasion or extrinsic compression by malignancies such as nonsmall cell lung cancer, lymphoma, metastases or thymomas.
•	A smaller portion of patients with SVC syndrome have non-malignant causes such as thrombosis, post-radiation fibrosis or an infectious
etiology.
•	Due to the increasing use of intravascular devices, such as central venous catheters and pacemaker/defibrillator leads, a larger portion
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of SVC syndromes now occur from benign causes which may account for up to 40% of SVC cases.
•	Treatment of SVC syndrome is accomplished by removing or attempting to decrease the size of the mass or thrombus causing the
obstruction and is guided by the etiology and severity of symptoms on presentation.
•	Options for treatment for SVC syndrome include: thrombolysis, endovascular stenting, balloon angioplasty, venous grafting or
mechanical thrombectomy.
•	Stent placement is a commonly used treatment and has been shown to be successful in both benign and malignant causes of SVC
3
syndrome.
4,5
•	In thrombus induced SVC syndrome, thrombolysis prior to stent placement has been shown to be successful, however, it has also
6
shown to increase morbidity therefore making this combined strategy less desirable.
7
•	Stent placement also has its own risks such as: infection, pulmonary emboli, stent migration, hematoma formation, or SVC rupture.
•	In this case, due to the large extent of clot burden, the patient had a combination of catheter directed tPA and balloon angioplasty.
•	After 62 hrs of tPA, infusion catheter check relieved excellent flow through the SVC therefore not requiring stent placement.
•	Patient’s symptoms significantly and quickly improved with the above treatment.

Conclusion
•	Due to the increasing use of intravascular devices, a larger portion of SVC syndromes now occur from benign causes.
•	Percutaneous angioplasty can be used as an adjunct to tPA therapy to accelerate clot dissolution and successfully treat thrombus
induced SVC syndrome, without the need for stent placement.
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